3,077 Shares in Veeva Systems Inc. (NYSE:VEEV) Purchased by Citizens Financial Group Inc. RI

Citizens Financial Group Inc. RI bought a new position in shares of Veeva Systems Inc. (NYSE:VEEV) during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 3,077 shares of the technology company’s stock, valued at approximately $563,000.

Several other large investors have also recently added to or reduced their stakes in the company. Advisors Asset Management Inc. acquired a new position in shares of Veeva Systems during the 1st quarter worth approximately $28,000. DSM Capital Partners LLC acquired a new stake in Veeva Systems during the fourth quarter worth approximately $29,000. Vermillion & White Wealth Management Group LLC bought a new position in Veeva Systems during the 4th quarter worth $32,000. Blue Trust Inc. raised its holdings in Veeva Systems by 3,460.0% in the 2nd quarter. Blue Trust Inc. now owns 178 shares of the technology company’s stock valued at $33,000 after acquiring an additional 173 shares in the last quarter. Finally, First Financial Corp IN bought a new stake in shares of Veeva Systems during the 1st quarter valued at $35,000. Institutional investors own 88.20% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms recently commented on VEEV. Evercore ISI dropped their price target on Veeva Systems from $230.00 to $200.00 and set an “in-line” rating for the company in a research note on Friday, May 31st. Truist Financial boosted their target price on shares of Veeva Systems from $197.00 to $207.00 and gave the company a “hold” rating in a research report on Tuesday, September 3rd. Morgan Stanley reduced their price target on shares of Veeva Systems from $210.00 to $173.00 and set an “underweight” rating on the stock in a research report on Friday, May 31st. Robert W. Baird boosted their price objective on shares of Veeva Systems from $245.00 to $251.00 and gave the company an “outperform” rating in a research report on Thursday, August 29th. Finally, JPMorgan Chase & Co. raised their target price on Veeva Systems from $203.00 to $208.00 and gave the company a “neutral” rating in a report on Monday, September 9th. One equities research analyst has rated the stock with a sell rating, seven have issued a hold rating and sixteen have given a buy rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $229.96.

Veeva Systems Price Performance

VEEV opened at $215.61 on Thursday. Veeva Systems Inc. has a fifty-two week low of $162.72 and a fifty-two week high of $236.90. The firm has a market capitalization of $34.91 billion, a price-to-earnings ratio of 63.60, a PEG ratio of 2.12 and a beta of 0.81. The company’s 50 day moving average price is $198.15 and its two-hundred day moving average price is $201.71.

Insider Buying and Selling

In other news, SVP Jonathan Faddis sold 2,353 shares of the stock in a transaction dated Wednesday, August 21st. The stock was sold at an average price of $200.00, for a total value of $470,600.00. Following the completion of the sale, the senior vice president now owns 9,035 shares of the company’s stock, valued at $1,807,000. The sale was disclosed in a legal filing with the SEC, which is available at this link. 10.50% of the stock is owned by corporate insiders.

Veeva Systems Profile

Veeva Systems Inc provides cloud-based software for the life sciences industry. It offers Veeva Commercial Cloud, a suite of software and analytics solutions, such as Veeva customer relationship management (CRM) that enable customer-facing employees at pharmaceutical and biotechnology companies; Veeva Vault PromoMats, an end-to-end content and digital asset management solution; Veeva Vault Medical that provides source of medical content across multiple channels and geographies; Veeva Crossix, an analytics platform for pharmaceutical brands; Veeva OpenData, a customer reference data solution; Veeva Link, a data application that allows link to generate real-time intelligence; and Veeva Compass includes de-identified and longitudinal patient data for the United States.